|Mr. Ronald H. W. Cooper||CEO, Pres & Director||899.19k||N/A||1963|
|Dr. Jan P. Mattsson||Chief Scientific Officer & MD (Sweden) and Co-Founder||525.27k||N/A||1964|
|Ms. Martha J. Carter||Chief Regulatory Officer||584.22k||N/A||1952|
|Dr. Per-Goran Gillberg||Co-Founder & VP of Devel.||N/A||N/A||N/A|
|Mr. Simon N.R. Harford||CFO & Treasurer||N/A||N/A||1961|
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat, an orally administered IBAT inhibitor for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of bile acid malabsorption. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Albireo Pharma, Inc.’s ISS Governance QualityScore as of December 3, 2019 is 8. The pillar scores are Audit: 10; Board: 4; Shareholder Rights: 7; Compensation: 5.